Published Date: 17 Mar 2023
Kottayam: Government General Hospital (GMC) Government of Kerala delay in paying Kottayam affects patient care and...
Read Full NewsHere's some of what is coming soon to NeurologyLive® this week.
Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine discussed the often-overlooked early signs of early-onset Alzheimer disease.
Gefurulimab (Klygefa), a once-weekly, self-administered complement C5 inhibitor from Alexion and AstraZeneca, is now approved in the US for adults with AChR-antibody-positive generalized myasthenia gravis.
A new FDA filing seeks to expand cenobamate's epilepsy indication to primary generalized tonic-clonic seizures, based on positive phase 3 trial data.
The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.
A new global phase 2 trial, TARBELA-AD, will test RG6434, Roche's investigational oral NLRP3 inflammasome inhibitor, in adults with early symptomatic Alzheimer disease.
A pivotal phase 2/3 trial of Zhimeng Biopharma's CB03-154, an oral KCNQ2/3 potassium channel opener, has completed enrollment in amyotrophic lateral sclerosis.
1.
CAR T-Cell Therapy in Functional High-Risk Multiple Myeloma
2.
According to a study, taking part in a clinical trial for cancer may not actually increase survival.
3.
Orca-T Approved to Prevent GVHD After Stem Cell Transplant for Blood Cancers
4.
Adjuvant Combination for Kidney Cancer Gets FDA's Blessing
5.
TKI Discontinuation Feasible After ALL Treatment
1.
Abemaciclib in Combination with Therapies for Patients with Metastatic Breast Cancer
2.
Importance of Early Detection in Hematology
3.
Reproductive Hormones and Immune Cell Metabolism: Mechanisms, Clinical Implications, and Emerging Evidence
4.
Clonal Hematopoiesis as a Mechanism of Age-Related Disease
5.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
2.
Efficient Management of First line ALK-rearranged NSCLC - Part II
3.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
4.
Expert Perspectives on Hematology
5.
Screening for Red Cell Membrane Disorders Through Ektacytometry-Based Deformability Profiling
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation